Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) PT at $106.75

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has received a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and three have assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $110.5455.

A number of brokerages have weighed in on GPCR. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Wall Street Zen lowered shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Citizens Jmp decreased their target price on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research report on Friday, February 27th. Finally, HC Wainwright lowered their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of Structure Therapeutics by 18.5% in the second quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after purchasing an additional 8,444 shares in the last quarter. Invesco Ltd. increased its holdings in Structure Therapeutics by 7.6% in the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock valued at $8,805,000 after buying an additional 30,162 shares during the period. Marshall Wace LLP increased its holdings in Structure Therapeutics by 474.9% in the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after buying an additional 145,434 shares during the period. Jump Financial LLC raised its stake in shares of Structure Therapeutics by 105.9% in the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after buying an additional 32,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Structure Therapeutics in the 2nd quarter valued at $3,480,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Up 2.2%

Shares of GPCR stock opened at $45.51 on Thursday. Structure Therapeutics has a 12 month low of $15.80 and a 12 month high of $94.90. The firm has a market cap of $3.23 billion, a PE ratio of -52.31 and a beta of -1.35. The stock has a 50 day moving average of $42.52 and a 200-day moving average of $57.75.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, equities analysts predict that Structure Therapeutics will post -1.64 EPS for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.